The industry giants – they are described as “top-10 global cosmetic companies” – will use Integumen’s Labskin AI to test some of their products in a real-world setting.
Together, the pair of contracts are worth in excess of £100,000, Integumen said, with the potential for continued testing thereafter.
“Integumen is playing a major role in the creation of an innovative AI eco-system that will contribute to the growth of our clients' product range as they develop new skin care products using the LabskinAI virtual platform,” said chief executive Gerry Brandon.
“Right now, LabskinAI serves as a portal for small, medium and large corporations to meet the strict EU regulatory requirements for existing products that are already on the shelf.
“The repeat custom of two global cosmetic companies is testament to the value of the LabskinAI platform for the entire skin care industry.”
In the same announcement, Integumen confirmed that LabskinAI has now completed Beta testing and has fully transitioned from a product sale only company to a virtual and physical test platform for healthcare, personal care, skincare, wound care and pharmaceutical drug discovery eco-system.